
==== Front
Mol Brain
Mol Brain
Molecular Brain
1756-6606
BioMed Central London

951
10.1186/s13041-022-00951-6
Micro Report
The cyclin G-associated kinase (GAK) inhibitor SGC-GAK-1 inhibits neurite outgrowth and synapse formation
Egawa Jun zjones@example.net

12
Arta Reza K. 1
Lemmon Vance P. 34
Muños-Barrero Melissa 3
Shi Yan 3
http://orcid.org/0000-0003-1474-3385
Igarashi Michihiro zjones@example.net

2
Someya Toshiyuki 1
1 grid.260975.f 0000 0001 0671 5144 Department of Psychiatry, School of Medicine, and Graduate School of Medical and Dental Sciences, Niigata University, 757 Asahimachi Dori-Ichibancho, Chuo-ku, Niigata, 951-8510 Japan
2 grid.260975.f 0000 0001 0671 5144 Department of Neurochemistry and Molecular Cell Biology, School of Medicine, and Graduate School of Medical and Dental Sciences, Niigata University, 757 Asahimachi Dori-Ichibancho, Chuo-ku, Niigata, 951-8510 Japan
3 grid.26790.3a 0000 0004 1936 8606 Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL USA
4 grid.26790.3a 0000 0004 1936 8606 Institute for Data Science and Computing, University of Miami Miller School of Medicine, Miami, FL USA
26 7 2022
26 7 2022
2022
15 688 4 2022
9 7 2022
© The Author(s) 2022
https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Protein kinases are responsible for protein phosphorylation and are involved in important signal transduction pathways; however, a considerable number of poorly characterized kinases may be involved in neuronal development. Here, we considered cyclin G-associated kinase (GAK) as a candidate regulator of neurite outgrowth and synaptogenesis by examining the effects of the selective GAK inhibitor SGC-GAK-1. SGC-GAK-1 treatment of cultured neurons reduced neurite length and decreased synapse number and phosphorylation of neurofilament 200-kDa subunits relative to the control. In addition, the related kinase inhibitor erlotinib, which has distinct specificity and potency from SGC-GAK-1, had no effect on neurite growth, unlike SGC-GAK-1. These results suggest that GAK may be physiologically involved in normal neuronal development, and that decreased GAK function and the resultant impaired neurite outgrowth and synaptogenesis may be related to neurodevelopmental disorders.

Supplementary Information

The online version contains supplementary material zjones@example.net/s13041-022-00951-6.

Keywords

Cyclin G-associated kinase (GAK)
SGC-GAK-1
Primary neuron culture
High content screening
http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science #20H03597 #21K07496 #18H04013 Egawa Jun Igarashi Michihiro Someya Toshiyuki amed#21gm1210007s0103 Igarashi Michihiro AMED#22gm1210007s0104 Igarashi Michihiro NIHNINDS R01NS100531 Lemmon Vance P. The State of FloridaThe Miami Project to Cure Paralysisthe W.G. Ross Foundationissue-copyright-statement© The Author(s) 2022
==== Body
pmcPhosphorylation is considered to be the most important protein modification in signal transduction pathways. Protein kinases are the responsible enzymes for this process, and there are more than 500 species of kinases encoded in the human genome [1]. However, most of these are not well characterized, and their exact biological roles or functions are not known. Neurons have more complex signaling pathways than other cells because of their role in synaptic plasticity [2], and there are potentially numerous events that involve uncharacterized protein kinases. For example, c-jun N-terminus protein kinase (JNK) is reported to be tightly related to axon growth and regeneration [3].

Cyclin G-associated kinase (GAK) is one such kinase that is not well characterized. This protein is a 160 kDa serine/threonine kinase, and the structure is comprised of a kinase domain at the N-terminus, a PTEN-like domain, a clathrin binding domain, and a C-terminal J domain [4, 5]. Neuron-specific GAK knockouts cause defects in the proliferation of neural progenitor cells in the hippocampal region, causing neuronal depletion and changes in brain morphology, and mouse pups were observed to survive only a few days after birth [6]. However, the effects of GAK on neurodevelopmental processes have not been well investigated. Therefore, we used SGC-GAK-1, which had an IC50 of 48 nM in the live cell target engagement assay [7, 8].

The experimental procedures are described in detail in Additional file 1. We investigated how selective inhibition of GAK using SGC-GAK-1 [9–12] affects neurite outgrowth and synaptogenesis in mouse hippocampal neurons, according to the scheme shown in Fig. 1A. For quantification, a high-throughput screening system, the microscope-based CellInsight™ CX5 High Content Screening platform (Thermo Fisher Scientific), was used. First, we compared the total neurite length per number of neurons of samples treated with eight concentrations of SGC-GAK-1 compared to the control as above. Total neurite length per number of neurons was significantly reduced at 5, 10, 20, and 40 μM SGC-GAK-1 compared to the control supplemented with DMSO alone (p < 0.05/8; Fig. 1B, C). Total neurite branch points per number of neurons were also significantly reduced at 10, 20, and 40 μM SGC-GAK-1 compared to the control supplemented with DMSO alone (p < 0.05/8; Additional file 2: Fig. S1). There was no significant difference in the number of neurons from 0.3125 to 10 μM SGC-GAK-1 compared to the control (Additional file 1: Table S1). In addition, we measured synapse formation using double-immunostaining of synaptophysin (presynaptic marker) and SHANK2 (postsynaptic marker), and the total number of synapses per number of neurons was also significantly reduced at 10, 20, and 40 μM SGC-GAK-1 compared to the control (DMSO alone; p < 0.05/8; Fig. 1D–F). There was also no significant difference in the number of neurons from 0.3125 to 5.0 μM SGC-GAK-1 compared to the control (Additional file 1: Table S1).Fig. 1 Effects of GAK inhibition on neurodevelopment in mice. A Outline of the procedure. The ROI is shown within the yellow dotted curves, in which synaptic puncta were quantified (Right). B Cell imaging of neurons treated with 10 μM SGC-GAK-1 or dimethysulfoxide (DMSO) as the control. C Total neurite length per number of neurons in samples treated with 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, and 40 μM SGC-GAK-1 or DMSO (N = 6, each concentration). D Cell imaging of neurons treated with DMSO and stained with anti-synaptophysin 1 and anti-SHANK2 antibodies. E Cell imaging of neurons treated with 10 μM SGC-GAK-1 and stained with anti-synaptophysin 1 and anti-SHANK2 antibodies. F Total number of synapses per number of neurons in samples treated with SGC-GAK-1 (same concentrations as in C) or DMSO (N = 6, each concentration). G Cell imaging of neurons treated with DMSO and stained with SMI-31 or NF-200. H Cell imaging of neurons treated with 2.5 μM SGC-GAK-1 and stained with SMI-31 or NF-200. I SMI-31 staining: Neurite intensity per number of neurons in samples treated with SGC-GAK-1 (same concentrations as in C) or DMSO. J NF200 staining: Neurite intensity per number of neurons in samples treated with SGC-GAK-1 (same concentrations as in C) or DMSO (N = 3, each concentration). K Cell imaging of neurons treated with 2.5 μM SGC-GAK-1, 2.5 μM erlotinib, or DMSO and stained with MAP2. L SGC-GAK-1 treatment: Neurite intensity per number of neurons (stained with MAP2) in samples treated with SGC-GAK-1 (same concentrations as in C and N = 3, each concentration) or DMSO (N = 6). M Erlotinib treatment: Neurite intensity per number of neurons (stained with MAP2) in samples treated erlotinib (N = 3, each concentration, which is the same as in C) or DMSO (N = 6). Image size: 899.04 µm × 899.04 µm (B, G, H, K); 455.44 µm × 455.44 µm (D, E). Total neurite length/number of neurons, total number of synapses/number of neurons, and total neurite intensity/number of neurons were significant (*) at p < 0.05/8 after Bonferroni's correction and the error bars indicate standard deviation

Next, we immunostained the cultured neurons after exposure to SGC-GAK-1, using NF-200 and SMI-31 antibodies specific to the phosphorylated neurofilament (NF)-200 kDa subunit, and analyzed the immunoreactivity intensity in neurites. In both SMI-31 and NF-200 staining, the neurite intensity decreased in proportion to the increase in SGC-GAK-1 concentration (p < 0.05/8). However, at 2.5 μM, a significant difference was observed only in the intensity of SMI-31 compared to the control (Fig. 1G–J). The result showed that SGC-GAK-1 inhibits the phosphorylation function of GAK even in the concentration range with low neuronal cytotoxicity. Thus, we concluded that phosphorylation of the NF-200 kDa subunit was inhibited by SGC-GAK-1 in growing neurites.

We compared the neurite intensity of neurons treated with SGC-GAK-1 and erlotinib, another protein kinase inhibitor structurally related to SGC-GAK-1 but with lower specificity to GAK [10, 13]. Neurons were treated with erlotinib as described for SGC-GAK-1. In neurons treated with 1.25, 2.5, 5, 10, and 20 μM SGC-GAK-1, the neurite intensity significantly decreased compared to the control (p < 0.05/8). Among them, there were no significant differences in the number of neurons for the 1.25, 2.5, and 5 μM concentrations (Fig. 1K–M). The results showed that SGC-GAK-1 more specifically affected neuronal development involving GAK than did erlotinib. SGC-GAK-1 is a specific inhibitor of GAK, making it an ideal choice for assessing GAK activity. The narrow kinome spectrum and potent cell target engagement make it a better choice for deconvoluting GAK biology than a clinical kinase inhibitor such as erlotinib, which primarily targets EGF receptor tyrosine kinases and has off-target effects on GAK [10, 13]. Erlotinib did not show effects similar to those of SGC-GAK-1 (Fig. 1K–M), indicating that the latter inhibitor affected neurite outgrowth and synaptogenesis via GAK specifically.

Neurodevelopmental disorders, such as autism spectrum disorders, which affect communication, cognition, social interaction, and other patterned behaviors, are currently known to be caused partly by genetic mutations of brain signaling molecules [14] including protein kinases [15]. As shown here, GAK is involved in the normal development of neurons, suggesting the possibility that this or related kinases play a role in the pathogenesis of such diseases. Previously, GAK was reported to be related to neuronal degeneration in Parkinson's disease by its enhancement of α-synuclein-mediated toxicity [16, 17]; however, no evidence for its relationship to neuronal development has been demonstrated to date. Clathrin adapter proteins were reported to be potential substrates for this kinase in in vitro experiments [18], and an ongoing search for other physiological and specific substrates for this kinase is needed.

In conclusion, using the high-throughput imaging quantification system, we showed that axon outgrowth and synaptogenesis are impeded by inhibiting the phosphorylation function of GAK. It was also demonstrated that SGC-GAK-1 inhibits the substrate phosphorylation function of GAK, and affects neurodevelopment to a greater extent than erlotinib. The novel findings of the present study demonstrated that reduced GAK function is associated with neurodevelopmental disorders as well as α-synuclein-mediated neurodegeneration.

Supplementary Information

Additional file 1: Table S1. The number of neurons

Additional file 2: Figure S1. Neurite branches were inhibited by SGC-GAK-1.

Acknowledgements

The authors are grateful to Professor John L. Bixby (Miami University Miller School of Medicine) for the informative discussions.

Author contributions

JE planned and designed the experiments, designed and directed the project, performed the experiments, and wrote the manuscript. RKA performed the experiments. VPL planned and designed the experiments, designed and directed the project, and wrote the manuscript. MMB performed the experiments. YS analyzed the data. MI planned and designed the experiments, designed and directed the project, and wrote the manuscript. TS directed the project. All authors read and approved the final manuscript.

Funding

This work was supported in part by JSPS KAKENHI (#20H03597 to TS, #21K07496 to JE, and #18H04013 to MI), AMED-CREST (#21gm1210007s0103 and #22gm1210007s0104 to MI), the NIH (NINDS R01NS100531 to VPL), the State of Florida (to VPL), the Miami Project to Cure Paralysis (to VPL), and the W.G. Ross Foundation (to VPL).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

All animal experiments were performed following approval from the Animal Resource Center of Niigata University.

Consent for publication

All authors consent to publication.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Graves LM Duncan JS Whittle MC Johnson GL The dynamic nature of the kinome Biochem J 2013 450 1 8 10.1042/BJ20121456 23343193
2. Bayer KU Schulman H CaM kinase: still inspiring at 40 Neuron 2019 103 380 815-93-1189/j.neuron.2019.05.033 31394063
3. Kawasaki A Okada M Tamada A Okuda S Nozumi M Ito Y Kobayashi D Yamasaki T Yokoyama R Shibata T Nishina H Yoshida Y Fujii Y Takeuchi K Igarashi M Growth cone phosphoproteomics reveals that GAP-43 phosphorylated by JNK is a marker of axon growth and regeneration iScience 2018 4 190 815-93-1189/j.isci.2018.05.019 30240740
4. Dzamko N Zhou J Huang Y Halliday GM Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis Front Mol Neurosci 2014 7 57 10.3389/fnmol.2014.00057 25009465
5. Zhang CX Engqvist-Goldstein AE Carreno S Owen DJ Smythe E Drubin DG Multiple roles for cyclin G-associated kinase in clathrin-mediated sorting events Traffic 2005 6 1103 1815-93-1189/j.1600-0854.2005.00346.x 16262722
6. Lee DW Zhao X Yim YI Eisenberg E Greene LE Essential role of cyclin-G-associated kinase (Auxilin-2) in developing and mature mice Mol Biol Cell 2815-93-1189 2815-93-1189/mbc.e07-11-1115 18434600
7. Asquith CRM Berger BT Wan J Bennett JM Capuzzi SJ Crona DJ Drewry DH East MP Elkins JM Fedorov O SGC-GAK-1: a chemical probe for Cyclin G Associated Kinase (GAK) J Med Chem 2815-93-1189 2815-93-1189/acs.jmedchem.8b01213 30768268
8. Cohen P Cross D Jänne PA Kinase drug discovery 20 years after imatinib: progress and future directions Nat Rev Drug Discov 2021 20 551 815-93-1189/s41573-021-00195-4 34002056
9. Asquith CRM Bennett JM Su L Laitinen T Elkins JM Pickett JE Wells CI Li Z Willson TM Zuercher WJ Towards the development of an in vivo chemical probe for Cyclin G associated kinase (GAK) Molecules 2815-93-1189 10.3390/molecules24224016
10. Asquith CRM Naegeli KM East MP Laitinen T Havener TM Wells CI Johnson GL Drewry DH Zuercher WJ Morris DC Design of a Cyclin G associated kinase (GAK)/epidermal growth factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in Chordoma J Med Chem 2815-93-1189 4815-93-1189/acs.jmedchem.9b00350 30973735
11. Asquith CRM Treiber DK Zuercher WJ Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK) Bioorg Med Chem Lett 2815-93-1189 1815-93-1189/j.bmcl.2019.05.025 31129055
12. Asquith CRM Laitinen T Bennett JM Wells CI Elkins JM Zuercher WJ Tizzard GJ Poso A Design and analysis of the 4-anilinoquin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure-activity relationship ChemMedChem 2020 15 26 49 10.1002/cmdc.201900521 31675459
13. Addeo R Zappavigna S Parlato C Caraglia M Erlotinib: early clinical development in brain cancer Expert Opin Investig Drugs 2815-93-1189 1815-93-1189/13543784.2014.918950
14. Li X Zou H Brown WT Genes associated with autism spectrum disorder Brain Res Bull 2012 88 543 815-93-1189/j.brainresbull.2012.05.017 22688012
15. Boksha IS Prokhorova TA Tereshkina EB Savushkina OK Burbaeva GS Protein phosphorylation signaling cascades in autism: the role of mTOR pathway Biochem Mosc 2021 86 577 815-93-1189/S0006297921050072
16. Beilina A Rudenko IN Kaganovich A Civiero L Chau H Kalia SK Kalia LV Lobbestael E Chia R Ndukwe K Ding J Nalls MA International Parkinson's Disease Genomics ConsortiumNorth American Brain Expression ConsortiumOlszewski M Hauser DN Kumaran R Lozano AM Baekelandt V Greene LE Taymans JM Greggio E Cookson MR Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease Proc Natl Acad Sci USA 2014 111 2626 2815-93-1189/pnas.1318306111 24510904
17. Dumitriu A Pacheco CD Wilk JB Strathearn KE Latourelle JC Goldwurm S Pezzoli G Rochet JC Lindquist S Myers RH Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson's disease: results from the Gene PD Study Hum Mol Genet 2815-93-1189 1815-93-1189/hmg/ddr026 21258085
18. Umeda A Meyerholz A Ungewickell E Identification of the universal cofactor (auxilin 2) in clathrin coat dissociation Eur J Cell Biol 2000 79 336 815-93-1189/S0171-9335(04)70037-0 10887964


{'source': 'PubMedDataset'}